Abstract
The Committee for Human Medicinal Products has recently recommended marketing authorization for retrovirus-mediated ex vivo gene therapy of patients' autologous CD34+ cells transduced with human ADA complementary DNA for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID).1 If confirmed by the European Commission, the product, called Strimvelis, would be the third approved gene therapy in the European Union. According to the CHMP opinion, “Strimvelis is indicated for the treatment of patients with severe combined immune deficiency due to ADA deficiency (ADA-SCID), for whom no suitable matched related stem cell donor is available.” The positive opinion includes a request to establish a post-treatment registry and long-term follow-up of the patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
